Beam Therapeutics Shares Positive Clinical Data

Beam Therapeutics has announced compelling updated clinical data from its ongoing Phase 1/2 trial for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD). The data indicates that treatment with 60 mg of BEAM-302 led to a mean steady-state total AAT level of 16.1 µM, with all patients consistently maintaining levels above the protective 11 µM threshold. These results support the advancement of the therapy towards pivotal development, showing promising efficacy and durability in patients with AATD.